✦ LIBER ✦

Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors

✍ Scribed by Okamoto, Isamu; Arao, Tokuzo; Miyazaki, Masaki; Satoh, Taroh; Okamoto, Kunio; Tsunoda, Takuya; Nishio, Kazuto; Nakagawa, Kazuhiko

Book ID: 119827163
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 131 KB
Volume: 103
Category: Article
ISSN: 1347-9032
DOI: 10.1111/cas.12014

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I clinical trial using peptide vac

Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer

✍ Motoki Miyazawa; Ryuji Ohsawa; Takuya Tsunoda; Seiko Hirono; Manabu Kawai; Masaj 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 641 KB

137 A phase I study of an oral vascular

137 A phase I study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients with advanced solid tumors

✍ Tolcher, A.; O'Leary, J.J.; DeBono, J.; Molpus, K.; Woodard, C.; Warnat, M.; Lia 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 148 KB

Phase I Clinical and Pharmacokinetic Stu

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

✍ Strumberg, D. 📂 Article 📅 2005 🏛 American Society of Clinical Oncology 🌐 English ⚖ 207 KB

Phase I Clinical and Pharmacokinetic Stu

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

✍ Strumberg, D. 📂 Article 📅 2005 🏛 American Society of Clinical Oncology 🌐 English ⚖ 207 KB

## Purpose BAY 43-9006 is a novel dual-action Raf kinase and vascular endothelial growth factor receptor inhibitor that inhibits tumor cell proliferation and angiogenesis. This study established the safety and pharmacokinetics of BAY 43-9006 in 69 patients with advanced refractory solid tumors.

Phase I Study of Neratinib in Combinatio

Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2-Dependent and Other Solid Tumors

✍ Gandhi, L.; Bahleda, R.; Tolaney, S. M.; Kwak, E. L.; Cleary, J. M.; Pandya, S. 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 521 KB

Vascular endothelial growth factor and i

Vascular endothelial growth factor and its type 2 receptor in tumors and serum of patients with renal cancer

✍ N. E. Kushlinsky; M. F. Trapeznikova; E. S. Gershtein; P. A. Glibin; I. A. Kazan 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 221 KB